Stratagene licenses genes from AROS to develop cancer diagnostic test kits

By E. Janene Geiss

Philadelphia, Sept. 8 - Stratagene Corp. said Friday that it has obtained an exclusive option to evaluate and license a family of patents and patent applications controlled by AROS Applied Biotechnology of Denmark.

Under the agreement, Stratagene said it will have the right to evaluate and exclusively license the rights to certain gene groups that have been shown to have predictive capabilities for certain cancers. Financial terms were not disclosed, according to a news release by the LaJolla, Calif., biotechnology company.

Access to sets of genes that have predictive capabilities for bladder cancer will allow the company to internally develop diagnostic test kits that should enable the detection of cancer at an earlier stage than is now possible, Stratagene said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.